ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Sanofi and Lunan Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

SanofiLunan Pharmaceutical Group
studies on the registry2,42539
open to participants now10419
phase 3 studies under way6110
reach primary completion within a year644
programswith a study of their own in two years80+12 named only20

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseSanofiLunan Pharmaceutical Group
Phase 128%

Lunan Pharmaceutical Group: 8 of its 20 programs at phase 1

  1. F182112phase 1
  2. LNF2007phase 1
  3. LNF2105phase 1
  4. Dronedaroneno phase
  5. Budesonideno phase

and 3 more — sign in to see them all

40%
Phase 2

Sanofi: 25 of its 80 programs at phase 2

  1. brivekimigphase 2
  2. Acne mRNA vaccinephase 2
  3. Daxokafusp Alfaphase 2
  4. RSV+HMPV vaccinephase 2
  5. efdoralprin alfaphase 2

and 20 more — sign in to see them all

31%

Lunan Pharmaceutical Group: 4 of its 20 programs at phase 2

  1. F182112+CD38phase 2
  2. mosapridephase 2
  3. Vonorasan fumarate injection1phase 2
  4. Vonorasan fumarate injection2phase 2
20%
Phase 3

Sanofi: 22 of its 80 programs at phase 3

  1. rilzabrutinibphase 3
  2. frexalimabphase 3
  3. Pneumococcal 21-Valent Conjugate Vaccinephase 3
  4. lunsekimigphase 3
  5. duvakitugphase 3

and 17 more — sign in to see them all

28%

Lunan Pharmaceutical Group: 8 of its 20 programs at phase 3

  1. rulonilimabphase 3
  2. Beclomethasonephase 3
  3. Cetirizinephase 3
  4. Diphenhydraminephase 3
  5. F027phase 3

and 3 more — sign in to see them all

40%
Approved, new studies

Sanofi: 11 of its 80 programs at approved, new studies

  1. dupilumabapproved, new study
  2. belumosudilapproved, new study
  3. sarilumabapproved, new study
  4. fitusiranapproved, new study
  5. Avapritinibapproved, new study

and 6 more — sign in to see them all

14%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Sanofi29 readouts · 10 phase 3

Sanofi, Nov ’26: 3 programs whose next study reaches primary completion, 3 in phase 3

  1. rilzabrutinibphase 3 · Nov 25 · NCT07216079
  2. NVX-CoV2373 adjuvated lipid nanoparticleapproved, new study · Nov 26 · NCT07861542
  3. Measles, combinations with mumps and rubella, live attenuatedphase 3 · Nov 28 · NCT07103148

Sanofi, Dec ’26: 4 programs whose next study reaches primary completion, 1 in phase 3

  1. Pandemic flu H5 HA mRNA SD2 vaccinephase 2 · Dec 1 · NCT06907511
  2. Pneumococcal 21-Valent Conjugate Vaccinephase 3 · Dec 1 · NCT06838000
  3. brivekimigphase 2 · Dec 17 · NCT06958536
  4. frexalimabphase 3 · Dec 23 · NCT06500702

Sanofi, Jan ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. efanesoctocog alfaapproved, new study · Jan 15 · NCT04644575
  2. RSV+HMPV vaccinephase 2 · Jan 18 · NCT06686654
  3. Daxokafusp Alfaphase 2 · Jan 19 · NCT05584670
  4. belumosudilapproved, new study · Jan 26 · NCT07726914
  5. rF1V-1018phase 2 · Jan 29 · NCT07207408

Sanofi, Feb ’27: 2 programs whose next study reaches primary completion, 2 in phase 3

  1. dupilumabapproved, new study · Feb 7 · NCT07905547
  2. itepekimabphase 3 · Feb 17 · NCT07424144

Sanofi, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fitusiranapproved, new study · Mar 25 · NCT05662319

Sanofi, Apr ’27: 6 programs whose next study reaches primary completion

  1. H5 Flu IMP 2phase 1 · Apr 4 · NCT07516418
  2. Inosine Monophosphatephase 1 · Apr 4 · NCT07516418
  3. RSV IMP 4phase 1 · Apr 4 · NCT07516418
  4. RSV IMP 5phase 1 · Apr 4 · NCT07516418
  5. RSV IMP 6phase 1 · Apr 4 · NCT07516418

and 1 more — sign in to see them all

Sanofi, May ’27: 1 program whose next study reaches primary completion

  1. SAR402663phase 2 · May 18 · NCT06660667

Sanofi, Jun ’27: 2 programs whose next study reaches primary completion

  1. lunsekimigphase 3 · Jun 21 · NCT06676319
  2. Avapritinibapproved, new study · Jun 23 · NCT03731260

Sanofi, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. riliprubartphase 3 · Jul 9 · NCT06290141

Sanofi, Aug ’27: 1 program whose next study reaches primary completion

  1. SAR448632phase 1 · Aug 15 · NCT07944885

Sanofi, Sep ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. zetrukibartphase 2 · Sep 22 · NCT07225569
  2. amlitelimabphase 3 · Sep 30 · NCT06241118

Sanofi, Oct ’27: 1 program whose next study reaches primary completion

  1. SAR446597phase 2 · Oct 13 · NCT07215234
Lunan Pharmaceutical Group4 readouts · 1 phase 3·

Lunan Pharmaceutical Group, Dec ’26: 1 program whose next study reaches primary completion

  1. LNF2007phase 1 · Dec 0 · NCT06752447
·

Lunan Pharmaceutical Group, Feb ’27: 2 programs whose next study reaches primary completion

  1. Vonorasan fumarate injection1phase 2 · Feb 0 · NCT06783257
  2. Vonorasan fumarate injection2phase 2 · Feb 0 · NCT06783257
···

Lunan Pharmaceutical Group, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Isosorbidephase 3 · Jun 30 · NCT06765993
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Sanofi

New programs 6

Reached a new phase 1

Study stopped 4

  • balinatunfibphase 2 · terminated Oct 22 · none of its studies left running“Business decision” · NCT07222189
  • balinatunfibphase 2 · terminated Oct 21 · none of its studies left running“Business decision” · NCT06867094
  • balinatunfibphase 2 · terminated Oct 13 · none of its studies left running“Business decision.” · NCT06637631
  • amlitelimabphase 2 · terminated Oct 2“Sponsor decision; the decision is not related to any safety concern.” · NCT06033833

Primary completion later 2

Lunan Pharmaceutical Group

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 12 in all. A program counts in each condition its studies name most.

ConditionSanofiLunan Pharmaceutical Group
Asthmaboth · compare here

Sanofi in Asthma: 5 programs

  1. lunsekimigphase 3
  2. duvakitugphase 3
  3. amlitelimabphase 3
  4. itepekimabphase 3
  5. dupilumabapproved, new study

Their studies: Sanofi’s studies of Asthma in search

Lunan Pharmaceutical Group in Asthma: 2 programs

  1. Beclomethasonephase 3
  2. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Asthma in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

Sanofi in Pulmonary Disease, Chronic Obstructive: 3 programs

  1. lunsekimigphase 3
  2. itepekimabphase 3
  3. dupilumabapproved, new study

Their studies: Sanofi’s studies of Pulmonary Disease, Chronic Obstructive in search

Lunan Pharmaceutical Group in Pulmonary Disease, Chronic Obstructive: 2 programs

  1. Beclomethasonephase 3
  2. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Pulmonary Disease, Chronic Obstructive in search

Colitis, Ulcerativeboth · compare here

Sanofi in Colitis, Ulcerative: 3 programs

  1. duvakitugphase 3
  2. brivekimigphase 2
  3. balinatunfibphase 2

Their studies: Sanofi’s studies of Colitis, Ulcerative in search

Lunan Pharmaceutical Group in Colitis, Ulcerative: 1 program

  1. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Colitis, Ulcerative in search

Multiple Myelomaboth · compare here

Sanofi in Multiple Myeloma: 1 program

  1. Anti-GPRC5D Monoclonal Antibody SAR446523phase 1

Their studies: Sanofi’s studies of Multiple Myeloma in search

Lunan Pharmaceutical Group in Multiple Myeloma: 3 programs

  1. F182112 single-agentphase 3
  2. F182112+CD38phase 2
  3. F182112phase 1

Their studies: Lunan Pharmaceutical Group’s studies of Multiple Myeloma in search

Diabetes Mellitus, Type 2both · compare here

Sanofi in Diabetes Mellitus, Type 2: 1 program

  1. iGlarLixi (insulin glargine/lixisenatide)approved, new study

Their studies: Sanofi’s studies of Diabetes Mellitus, Type 2 in search

Lunan Pharmaceutical Group in Diabetes Mellitus, Type 2: 2 programs

  1. F027phase 3
  2. Valsartanphase 3

Their studies: Lunan Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Lupus Erythematosus, Systemicboth · compare here

Sanofi in Lupus Erythematosus, Systemic: 2 programs

  1. frexalimabphase 3
  2. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lupus Erythematosus, Systemic in search

Lunan Pharmaceutical Group in Lupus Erythematosus, Systemic: 1 program

  1. F182112phase 1

Their studies: Lunan Pharmaceutical Group’s studies of Lupus Erythematosus, Systemic in search

Multiple Sclerosisboth · compare here

Sanofi in Multiple Sclerosis: 2 programs

  1. frexalimabphase 3
  2. Cholestyramine Resinphase 3

Their studies: Sanofi’s studies of Multiple Sclerosis in search

Lunan Pharmaceutical Group in Multiple Sclerosis: 1 program

  1. Diphenhydraminephase 3

Their studies: Lunan Pharmaceutical Group’s studies of Multiple Sclerosis in search

Carcinoma, Non-Small-Cell Lungboth · compare here

Sanofi in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Tadalafilphase 3

Their studies: Sanofi’s studies of Carcinoma, Non-Small-Cell Lung in search

Lunan Pharmaceutical Group in Carcinoma, Non-Small-Cell Lung: 1 program

  1. rulonilimabphase 3

Their studies: Lunan Pharmaceutical Group’s studies of Carcinoma, Non-Small-Cell Lung in search

Colorectal Neoplasmsboth · compare here

Sanofi in Colorectal Neoplasms: 1 program

  1. tusamitamab sonditecanphase 1

Their studies: Sanofi’s studies of Colorectal Neoplasms in search

Lunan Pharmaceutical Group in Colorectal Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Colorectal Neoplasms in search

Eosinophilic Esophagitisboth · compare here

Sanofi in Eosinophilic Esophagitis: 1 program

  1. dupilumabapproved, new study

Their studies: Sanofi’s studies of Eosinophilic Esophagitis in search

Lunan Pharmaceutical Group in Eosinophilic Esophagitis: 1 program

  1. Budesonideno phase

Their studies: Lunan Pharmaceutical Group’s studies of Eosinophilic Esophagitis in search

Lymphoma, B-Cellboth · compare here

Sanofi in Lymphoma, B-Cell: 1 program

  1. Anti-CD20 Bispecific Antibody DR-0201phase 1

Their studies: Sanofi’s studies of Lymphoma, B-Cell in search

Lunan Pharmaceutical Group in Lymphoma, B-Cell: 1 program

  1. Isosorbidephase 3

Their studies: Lunan Pharmaceutical Group’s studies of Lymphoma, B-Cell in search

Stomach Neoplasmsboth · compare here

Sanofi in Stomach Neoplasms: 1 program

  1. Daxokafusp Alfaphase 2

Their studies: Sanofi’s studies of Stomach Neoplasms in search

Lunan Pharmaceutical Group in Stomach Neoplasms: 1 program

  1. trifluridine tipiracil drug combinationno phase

Their studies: Lunan Pharmaceutical Group’s studies of Stomach Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

TargetSanofiLunan Pharmaceutical Group
PDCD1Daxokafusp Alfarulonilimabrule
A target, or a pathogen for a vaccine, known for: Sanofi 53 of 80 · Lunan Pharmaceutical Group 8 of 20 programs (18 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (Sanofi: 12).